Uzhachenko et al. reported that CDK4/6is are capable of promoting mTOR activity in mammary tumors; thus, inhibition of mTOR signaling might be a promising strategy in the context of CDK4/6i treatment (Figure 3d) [78]. Here, CDK4 is linked to breast cancer.